Inspection Record

Anderson Compounding Pharmacy, Inc. dba Anderson Compounding Pharmacy — FDA 483 Findings

US FDAInspected 2019-04-05Published 2019-09-16 4 findingsContamination controlAseptic processing and sterility assuranceOther quality system

Inspectors Xiaohui ShenThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

Non-microbial contamination was observed in your production area.

2Aseptic processing and sterility assurance

The ISO 5 classified aseptic processing areas had difficult to clean and visibly dirty equipment or surface.

3Contamination control

You produced hazardous drugs without providing adequate containment to prevent cross-contamination.

4Other quality system

Unsealed, loose ceiling tiles were observed in your cleamoom.

About this record

Extracted automatically from the document US FDA published on 2019-09-16. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Anderson Compounding Pharmacy, Inc. dba Anderson Compounding Pharmacy company profile — full history US FDA documents, 2019 Go to Findings search